| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
9,230,000 |
| Market
Cap: |
3.60(M) |
| Last
Volume: |
426,351 |
Avg
Vol: |
425,167 |
| 52
Week Range: |
$0.39 - $0.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company working to develop cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating CYC140, a Polo-Like-Kinase 1(PLK 1) inhibitor, in cancers. CDKs are a family of enzymes discovered as regulators of the cell cycle. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,956 |
7,956 |
7,956 |
| Total Buy Value |
$0 |
$26,374 |
$26,374 |
$26,374 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sems Lloyd |
Director |
– • – |
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
|
- |
|
| Henney Christopher S |
Director |
– • – |
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
|
- |
|
| Spiegel Robert J. |
Director |
– • – |
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
|
- |
|
| Dart Kenneth Bryan |
10% Owner |
– – • |
2017-07-19 |
4 |
B |
$2.00 |
$1,700,000 |
D/D |
850,000 |
2,167,261 |
2.45 |
- |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2017-02-23 |
4 |
B |
$4.34 |
$582,079 |
I/I |
134,200 |
559,900 |
1.5 |
- |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2017-02-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
425,700 |
|
- |
|
| Dart Kenneth Bryan |
10% Owner |
– – • |
2015-03-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,607,143 |
|
- |
|
| Chiao Judy |
V.P., Clin. Dev. & Reg. Aff. |
• – – |
2014-12-06 |
5 |
D |
$2.99 |
$9,305 |
D/D |
(3,112) |
58,008 |
|
- |
|
| Rombotis Spiro |
President & CEO |
• • – |
2014-12-06 |
5 |
D |
$2.99 |
$11,634 |
D/D |
(3,891) |
237,525 |
|
- |
|
| Barker Sam L |
Director |
– • – |
2014-11-20 |
4 |
B |
$3.00 |
$9,300 |
D/D |
3,100 |
3,100 |
2.39 |
- |
|
35 Records found
|
|
Page 2 of 2 |
|
|
